NASDAQ: GPCR - Structure Therapeutics Inc.

六个月盈利: -47.38%
股息率: 0.00%
部门: Healthcare

促销时间表 Structure Therapeutics Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

更多详情
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 20.4
每日价格变化: +3.19% (20.4)
每周价格变化: -6.94% (22.62)
每月价格变化: -13.48% (24.33)
3个月内价格变化: -32.64% (31.25)
六个月内的价格变化: -47.38% (40)
每年价格变化: -40.54% (35.4)
3年内价格变化: 0% (21.05)
5年内价格变化: 0% (21.05)
10年价格变化: 0% (21.05)
年初以来价格变化: -26.35% (28.58)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
全部的: 2.75

效率

姓名 意义 年级
ROA, % -18.58 0
ROE, % -19.77 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0536 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 640268.75 10
盈利能力 EPS, % 31968.75 10
全部的: 8
更多详情

机构 体积 分享, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETF分享, %本年盈利能力, %股息, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416
0.24522.420.84



导师 职称 支付 出生年份
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 年)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 年)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 年)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 年)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

地址: United States, South San Francisco. CA, 611 Gateway Boulevard - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://structuretx.com